Abstract
A variety of therapeutic regimens including corticosteroids, immunosuppressants, antiplatelet agents, and anticoagulants have been prescribed to stroke patients with antiphospholipid antibodies. Although some of these medications may be useful in reducing the risk of recurrent thromboembolic events and deserve further investigation, studies published to date do not establish the effectiveness of any specific treatment. We conclude that a prospective study should be undertaken to assess the management of patients with antiphospholipid antibodies.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Adrenal Cortex Hormones / therapeutic use
-
Antibodies / analysis*
-
Antibody Formation / drug effects
-
Anticoagulants / therapeutic use
-
Cerebrovascular Disorders / immunology*
-
Cerebrovascular Disorders / therapy
-
Hemostasis / drug effects
-
Humans
-
Immunization, Passive
-
Immunosuppressive Agents / therapeutic use
-
Phospholipids / immunology*
-
Plasma Exchange
-
Platelet Aggregation Inhibitors / therapeutic use
Substances
-
Adrenal Cortex Hormones
-
Antibodies
-
Anticoagulants
-
Immunosuppressive Agents
-
Phospholipids
-
Platelet Aggregation Inhibitors